Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 36 Issue 5
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2018  >  36(5): 475-478

CAO Ailin, TANG Yanling, QIAN Jiao, WANG Zhuo. Interventional analysis on the off-label drug use of alprostadil lipid microsphere injection[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 475-478. doi: 10.3969/j.issn.1006-0111.2018.05.022
Citation: CAO Ailin, TANG Yanling, QIAN Jiao, WANG Zhuo. Interventional analysis on the off-label drug use of alprostadil lipid microsphere injection[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 475-478. doi: 10.3969/j.issn.1006-0111.2018.05.022
shu

Interventional analysis on the off-label drug use of alprostadil lipid microsphere injection

doi: 10.3969/j.issn.1006-0111.2018.05.022

  • Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

  • Received Date: 2018-03-30
  • Rev Recd Date: 2018-06-12
  • Objective To investigate the application of Lipo-PEG1 injection in our hospital, analyze the rationality of its clinical application and evaluate the role of the administrative intervention in promoting the rational drug use in the hospital. Methods Based on the administrative guidelines announced on July 28, 2016, the data from 1 351 patients who received Lipo-PEG1 injection during July and August were collected and analyzed. Results Lipo-PEG1 injection is widely used in different departments at the hospital. 65.41% cases received this medication as off-label indications. 99.85% cases used this drug with impropriate dosage and indications. 0.39% cases had contraindications. There was no difference before and after the administrative intervention. Conclusion The off-label use of Lipo-PEG1 injection is very common in clinical practice. More clinical attention should be paid to this problem. The results from simple administrative intervention is unsatisfied.
  • [1] 杨宝峰.药理学[M].北京:人民卫生出版社,2016:281-282.
    [2] PMDA.前列地尔注射液说明书[EB/OL].(2005-05-11)[2018-02-01]. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400315_2190406A1063_2_07.
    [3] 罗青,苟卫.前列地尔脂微球载体制剂治疗肝脏疾病的应用[J].中日友好医院学报,2007,21(1):50-51.
    [4] 张伶俐,李幼平,曾力楠,等.15国超说明书用药政策的循证评价[J].中国循证医学杂志,2012,12(4):426-435.
    [5] 张云,李月婷. 前列地尔注射液联合阿魏酸哌嗪对老年高血压肾病的疗效及对Cys-C、CRP的影响[J].中国老年学杂志,2017,37(21):5278-5280.
    [6] 卞丽丽,尚文斌.缬沙坦联合前列地尔治疗糖尿病肾病的Meta分析[J].中华内分泌代谢杂志,2015,31(5):408-412.
    [7] 李凤玲.前列地尔注射剂治疗慢性肾功能不全35例疗效观察[J].苏州大学学报(医学版),2007,27(6):929-930.
    [8] 王晓琳,栾瀚森,杨莉,等.国外上市新型注射剂的研究进展[J].中国医药工业杂志,2012,43(1):60-67.
    [9] YAMAUCHI K, YASUNAGA S, KAWASAKI H, et al. An approach to predict the ductus-arteriosus dilating effect induced by lipo-prostaglandin E1 in newborn rats lacking plasma concentration-time data by the pharmacological response kinetic model[J]. Biol Pharm Bull,2003,26(2):210-215.
    [10] 夏迎春.1767例住院患者使用前列地尔注射液回顾性调查[J].中国药师,2014,17(9):1541-1543.
    [11] 田方圆,邹敏,吴斌,等.前列地尔注射液不同给药方式致静脉炎的系统评价[J].中国药房,2017,28(21):2955-2958.
    [12] 中国老年学学会老年医学会老年内分泌代谢专业委员会.老年糖尿病诊疗措施专家共识(2013年版)[J].中华内科杂志,2014,53(3):243-251.
    [13] 左祥荣,郑崇明,曹权,等.呋塞米联合前列腺素E1微量泵注治疗急性肾衰竭[J].临床麻醉学杂志,2008, 24(8):693-695.
    [14] HONG L,ZHANG J,SHEN J. Clinical efficacy of different doses of lipo-prostaglandin E1 in the treatment of painful diabetic peripheral neuropathy[J]. J Diabetes Complicat, 2015, 29(8):1283-1286.
    [15] 叶戴萍.不同剂量前列地尔注射液治疗急性肝炎重症型的观察及护理[J].齐齐哈尔医学院学报,2001,22(11):1303-1304.
    [16] 韦敏.前列地尔维持给药的稳定性考察[J].中国药师,2008,11(1):68-69.
    [17] 李贤峰,王兆君.前列地尔治疗心力衰竭的疗效与安全性研究进展[J].中国误诊学杂志,2009,9(19):4553-4554.
    [18] 广东省药学会. 关于印发《超药品说明书用药目录(2017年版)》的通知[EB/OL].(2017-07-14)[2018-02-01].http://www.sinopharmacy.com.cn/notification/1092.html.
    [19] 徐丽丽,张利斌,吴文飞,等.基于超说明书用药潜在安全隐患的思考及管理对策[J].药学服务与研究,2013,13(5):347-349.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2970) PDF downloads(841) Cited by()

Related
Proportional views

Interventional analysis on the off-label drug use of alprostadil lipid microsphere injection

doi: 10.3969/j.issn.1006-0111.2018.05.022
  • Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
  • Received Date: 2018-03-30
  • Rev Recd Date: 2018-06-12

Abstract: Objective To investigate the application of Lipo-PEG1 injection in our hospital, analyze the rationality of its clinical application and evaluate the role of the administrative intervention in promoting the rational drug use in the hospital. Methods Based on the administrative guidelines announced on July 28, 2016, the data from 1 351 patients who received Lipo-PEG1 injection during July and August were collected and analyzed. Results Lipo-PEG1 injection is widely used in different departments at the hospital. 65.41% cases received this medication as off-label indications. 99.85% cases used this drug with impropriate dosage and indications. 0.39% cases had contraindications. There was no difference before and after the administrative intervention. Conclusion The off-label use of Lipo-PEG1 injection is very common in clinical practice. More clinical attention should be paid to this problem. The results from simple administrative intervention is unsatisfied.

CAO Ailin, TANG Yanling, QIAN Jiao, WANG Zhuo. Interventional analysis on the off-label drug use of alprostadil lipid microsphere injection[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 475-478. doi: 10.3969/j.issn.1006-0111.2018.05.022
Citation: CAO Ailin, TANG Yanling, QIAN Jiao, WANG Zhuo. Interventional analysis on the off-label drug use of alprostadil lipid microsphere injection[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(5): 475-478. doi: 10.3969/j.issn.1006-0111.2018.05.022
shu

    HTML

Reference (19)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return